REGULATORY

PAFSC First Committee on New Drugs to Discuss Approval of Japan’s First FD Treatment

January 28, 2013
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs, an advisory organ of the Minister of Health, Labor and Welfare, will meet on February 7 to discuss whether to recommend approval for five products including Acofide Tablets…

To read the full story

REGULATORY

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…